Merck prices oral PCSK9 pill Lipfendra at $315 a month

Merck sets a discount to injectables

Merck is launching Lipfendra at $315 per month, BioSpace reported. RBC Capital Markets called the $315 list price a 'meaningful discount' to injectable PCSK9 inhibitors, which range from $500 to $600 a month, in a note to investors. Pulse 2.0 reported the list price is roughly half the monthly cost of existing injectable PCSK9 inhibitors and that Merck indicated insured patients will likely pay substantially less.

What the FDA cleared

The FDA approved Lipfendra (enlicitide) as a 20 mg once-daily tablet for adults with hypercholesterolemia, including HeFH, as an adjunct to diet and exercise. Merck announced the approval on 16 July 2026, making Lipfendra the first oral PCSK9 inhibitor in the US. Medical Daily reported that every previously approved drug in this class was an injection and that Merck beat AstraZeneca to market, with AstraZeneca's oral candidate AZD0780 still in development. The review ran through the FDA's Commissioner's National Priority Voucher program, and BioSpace's tracking counts Lipfendra as the ninth approval under that pathway.

The market and the sales forecast

DelveInsight put the PCSK9 inhibitor market at $3 billion in 2025 across the US, four European Union countries, the UK and Japan, and counted about 230,000 diagnosed prevalent cases of HeFH in the US that year. RBC estimates peak sales of around $5 billion by 2034 for Lipfendra.

Trial results

In CORALreef Lipids, published in the New England Journal of Medicine, 2,909 patients formed the intention-to-treat group. LDL cholesterol fell 57.1% at week 24 with enlicitide and rose 3.0% with placebo, a between-group difference of 55.8 percentage points. At week 52, the between-group difference was 47.6 percentage points.

In CORALreef HeFH, the placebo-adjusted LDL reduction was 59% at 24 weeks, BioSpace reported. The most common adverse event in that trial was diarrhea. In CORALreef AddOn, enlicitide cut LDL by about 65% versus about 37% for ezetimibe plus bempedoic acid in just over 300 patients on background statin therapy, Ann Marie Navar, who presented the trial, said.

Uptake and patient numbers

Navar said up to 40% of cardiologists and well over 90% of primary care doctors have never prescribed an injectable PCSK9 inhibitor. Medical Daily reported that an estimated 73 million Americans have high LDL cholesterol and that HeFH affects roughly 1 in 250 Americans. STAT reported that the approval arrived as new clinical guidelines support a more aggressive approach to lowering cholesterol.

What the approval does not show

Pulse 2.0 reported that the approval rests on LDL lowering, not on evidence that Lipfendra cuts heart attacks, strokes or deaths. Merck is evaluating the drug for cardiovascular morbidity and mortality. The outcome work sits in CORALreef Outcomes, which has more than 14,500 enrolled participants, according to Pulse 2.0. The trial's projected completion date is December 2029. A STAT commentary by a cardiologist argued that the question of whom enlicitide helps is more complicated than the breakthrough framing.